Product: Systane iLux2 Meibomian Gland Dysfunction (MGD) Thermal Pulsation System
Top Line: Alcon is introducing its latest dry eye innovation, the Systane iLux2 Meibomian Gland Dysfunction (MGD) Thermal Pulsation System.
Close Up: With new imaging technology to capture infrared photos and HD video of the meibomian glands, this all-in-one handheld device allows patients to see the need for treatment and visualize their procedure, and experience results in as little as one week. The Systane iLux2 MGD Thermal Pulsation System expands Alcon’s current dry eye treatment offerings and allows practitioners to tailor MGD treatment to the needs of each of their patients in eight to twelve minutes. 
The device’s imaging technology allows patients to view both their meibomian glands and treatment through infrared imaging and HD video of the procedure. 
ECPs can customize heat and compression across each easy-to-visualize treatment zone.
Systane iLux2 MGD Thermal Pulsation System can help eyecare practitioners build a strong, trusting relationship with their patients by boosting the credibility of their treatment recommendation through direct visualization of the disease and tracking the disease over time through stored meibomian gland images, according to Alcon. “Alcon is dedicated to the advancement of medical device technology and providing eyecare professionals (ECPs) with the tools needed to effectively treat their patients,” said Fred Ellis, vice president, U.S. pharmaceutical and dry eye, Alcon. “With the Systane iLux2 MGD Thermal Pulsation System, ECPs will be able to further patient trust and confidence because seeing is believing.” 
Eric D. Donnenfeld, M.D., FAAO, Ophthalmic Consultants of Long Island, N.Y., noted that 56 percent of MGD patients see four or more eyecare practitioners in search of proper diagnosis and relief. “This is a prevalent diagnosis in my practice, and it is essential for me to stay on top of the latest treatment options,” said Dr. Donnenfeld. “The new Systane iLux2 MGD Thermal Pulsation System gives me the confidence to customize treatments based on my patients’ needs and help them see, understand and value their MGD treatment.”
Click here to watch a video about Systane iLux2.
Vital Stats: The Systane iLux2 is indicated for the application of localized heat and pressure therapy in adult patients with meibomian gland dysfunction (MGD), which is associated with evaporative dry eye, and to capture/store digital images and video of the meibomian glands. Contraindications: Do not use the Systane iLux2 in patients with the following conditions: patients whose pupils have been pharmaceutically dilated; patients with ocular injury or trauma, chemical burns, or limbal stem cell deficiency (within prior three months); patients with active ocular herpes zoster or simplex of eye or eyelid or a history of these within prior three months; patients with cicatricial lid margin disease; patients with active ocular infection, active ocular inflammation or history of chronic, recurrent ocular inflammation within prior three months; patients with an ocular surface abnormality that may compromise corneal integrity; patients with lid surface abnormalities that affect lid function in either eye; patients with aphakia; or patients with permanent makeup or tattoos on their eyelids.
The disposable may not fit all eyes, such as eyes with small palpebral fornices. Use of the Systane iLux2 is not recommended in patients with the following conditions: moderate to severe allergic, vernal or giant papillary conjunctivitis; severe eyelid inflammation; systemic disease conditions that cause dry eye; in patients who are taking medications known to cause dryness; patients with punctal plugs, or patients who have undergone ocular surgery within prior three months.
SystaneiLux.com; iLUX@alcon.com